

Dated: January 5, 2007  
Customer No.: 25,666  
Seventh Floor, Kalamazoo Building  
107 West Michigan Avenue  
Kalamazoo, MI 49007  
(269) 382-0030

Enclosure: Listing of Claims

\*\*\*\*\*


**THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.**

- 1 -

LISTING OF CLAIMSRECEIVED  
CENTRAL FAX CENTER  
JAN 05 2007

## CLAIMS 1-28 (canceled)

29. (previously presented) A compound of formula (I),



5 wherein :

- R<sub>1</sub> and R<sub>2</sub>, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,
- R<sub>3</sub> represents halogen, alkoxy, an optionally substituted aryl group or NR'<sub>1</sub>R'<sub>2</sub> wherein R'<sub>1</sub> and R'<sub>2</sub>, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,
- R<sub>4</sub> represents hydrogen or NR''<sub>1</sub>R''<sub>2</sub> wherein R''<sub>1</sub> and R''<sub>2</sub>, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,

15 its enantiomers, diastereoisomers, tautomers and addition salts thereof with a pharmaceutically acceptable acid or base,

it being understood that :

- the term "alkyl" denotes linear or branched hydrocarbon chain having from 1 to 8 carbon atoms,
- the term "alkoxy" denotes alkyl-oxy wherein the alkyl chain is linear or branched and has from 1 to 8 carbon atoms,
- the term "aryl" denotes phenyl or naphthyl,


- 2 -

- the term "heterocycle" denotes a mono- or bi-cyclic system which has from 5 to 11 carbon atoms and which may contain, in addition to the nitrogen atom to which  $R_1R_2$ ,  $R'_1R'_2$  or  $R''_1R''_2$  are bonded, one or two further hetero atoms selected from oxygen, sulphur and nitrogen, it being possible for the heterocyclic system to be substituted by one, two or three alkyl groups,

- the term "substituted" associated with aryl indicates that the phenyl or naphthyl group is substituted by one, two or three identical or different groups selected from halogen, alkyl, alkoxy, polyhaloalkyl and hydroxy,

- "polyhaloalkyl" denotes a linear or branched carbon chain having from 1 to 3 carbon atoms and from 1 to 7 halogen atoms.

30. (previously presented) A compound of Claim 29, which is represented by formula (I'),



31. (previously presented) A compound of Claim 29, wherein  $NR_1R_2$  represents  $NH_2$ , di-*n*-propylamine or morpholine.

32. (previously presented) A compound of Claim 30, wherein  $NR_1R_2$  represents  $NH_2$ , di-*n*-propylamine or morpholine.

33. (previously presented) A compound of Claim 29, wherein  $R_3$  represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

34. (previously presented) A compound of Claim 30, wherein  $R_3$  represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

US Serial No. 10/533,697

Supplemental Response and Amendment of January 5, 2007

Servier 457 PCT

- 3 -

35. (previously presented) A compound of Claim 29, wherein R<sub>4</sub> represents hydrogen, morpholine or azepine.

36. (previously presented) A compound of Claim 30, wherein R<sub>4</sub> represents hydrogen, morpholine or azepine.

37. (previously presented) A compound of Claim 29 which is selected from :

2-(dipropylamino)-8-(4-thiomorpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azocanyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-((4 $\alpha$ ,8 $\alpha$ )-octahydro-1(2*H*)-quinolyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-((4 $\alpha$ ,8 $\alpha$ )-octahydro-1(2*H*)-quinolyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

6,8-di(1-azepanyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azepanyl)-2-(dipropylamino)-6-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azepanyl)-2,6-di(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-amino-8-[(3 $\alpha$ ,5 $\beta$ )-3,5-dimethylmorpholinyl]pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-amino-8-[(3 $\alpha$ ,5 $\alpha$ )-3,5-dimethylmorpholinyl]pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-[(3 $\alpha$ ,5 $\beta$ )-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-[(3 $\alpha$ ,5 $\alpha$ )-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-[(3 $\alpha$ ,5 $\alpha$ )-3,5-dimethylmorpholinyl]-2-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-amino-8-(1-azepanyl)-6-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-chloro-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-(dipropylamino)-8-(1-pyrrolidinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

and 8-(3,4-dimethoxyphenyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one.

38. (currently amended) A method for treating a living animal body, including a human, afflicted with a condition selected from cancer, ~~non-insulin-dependent, type II diabetes, obesity, and hyperlipidaemia, hypercholesterolaemia and cardiovascular complications~~

US Serial No. 10/533,697

Supplemental Response and Amendment of January 5, 2007

Servier 457 PCT

- 4 -

~~thereof, arthrosis, and arterial hypertension~~, comprising the step of administering to the living animal body, ~~including a human~~, an amount of a compound of Claim 29 which is effective for alleviation of the condition.

39. (canceled)

5 40. (new) A method for treating a living animal body, ~~including a human~~, afflicted with cancer, comprising the step of administering to the living animal body, ~~including a human~~, an amount of a compound of Claim 29 which is effective for alleviation of cancer.

41. (canceled)

10 42. (canceled)

43. (new) The method of Claim 38, wherein the living animal body is a human.

44. (new) The method of Claim 40, wherein the living animal body is a human.

15

45. (new) A pharmaceutical composition, comprising as active principle an effective amount of a compound of Claim 29, together with one or more pharmaceutically acceptable excipients or vehicles.

20

---

US Serial No. 10/533,697  
Supplemental Response and Amendment of January 5, 2007  
Servier 457.PCT